ArticlemBio2022
Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children.
Open access · goldAbstract read
In one paragraph
Article in mBio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- A booster dose of an inactivated SARS-CoV-2 vaccine targeting virus variants sustains protective humoral and cellular immunity.BMC medicine · 2025Trial
- Immunogenicity and safety of CoronaVac vaccine in children and adolescents (Immunita-002, Brazil): A phase IV six-month follow up.Scientific reports · 2025Trial
- Impact of Vaccines Across the Lifespan: A New Perspective in Public Health-Conclusions of an Expert Panel-Part 2.Vaccines · 2026Review
- Age and primary vaccination schedule impact humoral and cellular immunity with an inactivated SARS-CoV-2 vaccine.iScience · 2025Article
- Therapeutic challenges in central nervous system viral infections: advancing mesenchymal stem cell-based strategies for treating neuroinflammation and promoting tissue repair.Frontiers in immunology · 2025Review
- Immune memory reactivation and T cell dynamics following 12-month homologous CoronaVac booster: a longitudinal cohort study.Frontiers in immunology · 2025Article
- Booster Vaccination with BNT162b2 Improves Cellular and Humoral Immune Response in the Pediatric Population Immunized with CoronaVac.Vaccines · 2024Article
- Immunogenicity of the CoronaVac vaccine in children: a real-world study.Frontiers in immunology · 2024Article
- Preclinical immunogenicity risk assessment of biotherapeutics using CD4 T cell assays.Frontiers in immunology · 2024Article
- Pathophysiological, immunological, and inflammatory features of long COVID.Frontiers in immunology · 2024Review
- Immune responses during COVID-19 breakthrough cases in vaccinated children and adolescents.Frontiers in immunology · 2024Article
- New insights into the pathogenesis of SARS-CoV-2 during and after the COVID-19 pandemic.Frontiers in immunology · 2024Review
- Innate and Adaptive Cell-Mediated Immune Responses to a COVID-19 mRNA Vaccine in Young Children.Open forum infectious diseases · 2023Article
- Comparative Immune Response after Vaccination with SOBERANAVaccines · 2023Article
- Article
- Real-World Effectiveness of Primary Series and Booster Doses of Inactivated Coronavirus Disease 2019 Vaccine Against Omicron BA.2 Variant Infection in China: A Retrospective Cohort Study.The Journal of infectious diseases · 2023Article
- A Review of Inactivated COVID-19 Vaccine Development in China: Focusing on Safety and Efficacy in Special Populations.Vaccines · 2023Review
- Review
- Statistical explanation of the protective effect of four COVID-19 vaccine doses in the general population.Frontiers in public health · 2023Article
- Panorama of Breakthrough Infection Caused by SARS-CoV-2: A Review.Medicina (Kaunas, Lithuania) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
57 authors at 13 institutions in 3 countries.
Jorge A Soto *Millennium Institute on Immunology and Immunotherapy, Santiago, Chile.ORCID 0000-0003-0335-9759
Felipe Melo-González *Millennium Institute on Immunology and Immunotherapy, Santiago, Chile.ORCID 0000-0002-3711-2407
Cristián Gutierrez-Vera *Millennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Bárbara M Schultz *Millennium Institute on Immunology and Immunotherapy, Santiago, Chile.ORCID 0000-0002-6201-6978
Roslye V Berríos-RojasMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Daniela Rivera-PérezMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Alejandro Piña-IturbeMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Guillermo Hoppe-ElsholzMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Luisa F DuarteMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.ORCID 0000-0003-1828-1800
Yaneisi VázquezMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Daniela Moreno-TapiaMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Mariana RíosMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Pablo A PalaciosMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Richard Garcia-BetancourtMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Álvaro SantibañezMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Gaspar A PachecoMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.ORCID 0000-0001-5748-5027
Constanza MendezMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Catalina A AndradeMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.ORCID 0000-0003-2623-1387
Pedro H SilvaMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Benjamín Diethelm-VarelaMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Patricio AstudilloDepartamento de Enfermedades Infecciosas e Inmunología Pediátricas, División de Pediatría, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Mario CalvoInstituto de Pediatría, Facultad de Medicina, Universidad Austral de Chile, Valdivia, Chile.
Antonio CárdenasDepartamento de Ciencias Médicas, Facultad de Medicina y Odontología, Universidad de Antofagasta, Antofagasta, Chile.
Marcela GonzálezHospital Dr. Gustavo Fricke, Valparaiso, Chile.
Macarena GoldsackDepartamento de Enfermedades Infecciosas e Inmunología Pediátricas, División de Pediatría, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Valentina GutiérrezDepartamento de Enfermedades Infecciosas e Inmunología Pediátricas, División de Pediatría, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Marcela PotinDepartamento de Enfermedades Infecciosas e Inmunología Pediátricas, División de Pediatría, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Andrea SchillingFacultad de Medicina, Clínica Alemana, Universidad del Desarrollo, Santiago, Chile.
Lorena I TapiaDepartamento de Pediatría y Cirugía Infantil Norte, Hospital Roberto del Río, Santiago, Chile.
Loreto TweleHospital Puerto Montt, Puerto Montt, Chile.
Rodolfo VillenaHospital Exequiel González Cortés, Santiago, Chile.
Alba GrifoniCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, California, USA.ORCID 0000-0002-2209-5966
Alessandro SetteCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, California, USA.ORCID 0000-0001-7013-2250
Daniela WeiskopfCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, California, USA.ORCID 0000-0003-2968-7371
Rodrigo A FasceDepartamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile, Santiago, Chile.
Jorge FernándezDepartamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile, Santiago, Chile.
Judith MoraDepartamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile, Santiago, Chile.
Eugenio RamírezDepartamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile, Santiago, Chile.
Aracelly Gaete-ArgelMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Mónica L AcevedoMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Fernando Valiente-EcheverríaMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.ORCID 0000-0001-9156-2516
Ricardo Soto-RifoMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Angello Retamal-DíazMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Nathalia Muñoz-JofréDepartamento de Tecnología Médica, Facultad de Ciencias de la Salud, Universidad de Antofagasta, Antofagasta, Chile.
PedCoronaVac03CL Study Group,
Xing MengSinovac Biotechgrid.274690.e, Beijing, China.
Qianqian XinSinovac Biotechgrid.274690.e, Beijing, China.
Eduardo Alarcón-BustamanteFaculty of Mathematics, Pontificia Universidad Católica de Chile, Santiago, Chile.
José V González-AramundizDepartamento de Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago, Chile.
Nicole Le CorreDepartamento de Enfermedades Infecciosas e Inmunología Pediátricas, División de Pediatría, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
María Javiera Álvarez-FigueroaDepartamento de Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago, Chile.
Pablo A GonzálezMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.ORCID 0000-0001-7709-6870
Katia AbarcaMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.ORCID 0000-0003-0404-3887
Cecilia PerretDepartamento de Enfermedades Infecciosas e Inmunología Pediátricas, División de Pediatría, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Leandro J CarreñoMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.ORCID 0000-0003-2037-7158
Susan M BuenoMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.ORCID 0000-0002-7551-8088
Alexis M KalergisMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.ORCID 0000-0001-7622-5263
Pontificia Universidad Católica de Chile · CLMillennium Institute on Immunology and Immunotherapy · CLInstituto de Salud Pública de Chile · CLUniversidad de Antofagasta · CLHospital Dr. Gustavo Fricke · CLLa Jolla Institute for Immunology · USHospital Roberto del Rio · CLSan Sebastián University · CLSinovac Biotech · CNUniversidad Andrés Bello · CLUniversidad del Desarrollo · CLUniversity of Chile · CLAustral University of Chile · CL
Funding
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00016 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI WEBBY, RICHARD · 2021 to 2025
$91.4MLarge Scale T Cell Epitope Discovery:Global identification of epitopes derived from Zika (ZIKV), Chikungunya (CHIKV) viruses following natural infection and vaccination75N93019C00065 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI MITCHELL, MAYA · 2019 to 2023
$7.3MNIAID NIH HHS 75N93019C00065NIAID NIH HHS 75N93021C00016
Abstract
Multiple vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been evaluated in clinical trials. However, trials addressing the immune response in the pediatric population are scarce. The inactivated vaccine CoronaVac has been shown to be safe and immunogenic in a phase 1/2 clinical trial in a pediatric cohort in China. Here, we report interim safety and immunogenicity results of a phase 3 clinical trial for CoronaVac in healthy children and adolescents in Chile. Participants 3 to 17 years old received two doses of CoronaVac in a 4-week interval until 31 December 2021. Local and systemic adverse reactions were registered for volunteers who received one or two doses of CoronaVac. Whole-blood samples were collected from a subgroup of 148 participants for humoral and cellular immunity analyses. The main adverse reaction reported after the first and second doses was pain at the injection site. Four weeks after the second dose, an increase in neutralizing antibody titer was observed in subjects relative to their baseline visit. Similar results were found for activation of specific CD4
Indexed as
COVID-19SARS-CoV-2AdolescentAntibodies, NeutralizingAntibodies, ViralChildChild, PreschoolCOVID-19 VaccinesHumansVaccines, InactivatedAntibodies, NeutralizingAntibodies, ViralCOVID-19 Vaccinessinovac COVID-19 vaccineVaccines, InactivatedCoronaVacCOVID-19immunogenicitypediatricphase 3 clinical trialsafetySARS-CoV-2vaccinesvariants of concern
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.